A Comparative Study on the Effects of Nicotine and GTS-21, a New Nicotinic Agonist, on the Locomotor Activity and Brain Monoamine Level.

DOI Web Site Web Site Web Site Web Site View 1 Remaining Hide 1 Citations 24 References
  • Nanri Masato
    Department of Pharmacology, Taiho Pharmaceutical Co., Ltd. Department of Pharmacology, Research Institute for Wakan-Yaku (Oriental Medicines), Toyama Medical and Pharmaceutical University
  • Kasahara Nobuo
    Department of Pharmacology, Taiho Pharmaceutical Co., Ltd.
  • Yamamoto Jyunji
    Department of Pharmacology, Taiho Pharmaceutical Co., Ltd.
  • Miyake Hidekazu
    Department of Pharmacology, Taiho Pharmaceutical Co., Ltd.
  • Watanabe Hiroshi
    Department of Pharmacology, Research Institute for Wakan-Yaku (Oriental Medicines), Toyama Medical and Pharmaceutical University

Bibliographic Information

Other Title
  • A Comparative Study on the Effects of N

Search this article

Abstract

Effects of GTS-21 [3-(2, 4-dimethoxybenzylidene)-anabaseine dihydrochloride], a selective nicotinic agonist, on locomotor activity and dopamine turnover were examined and compared to those of nicotine to test if GTS-21 exhibits side effects similar to those of nicotine. GTS-21 had no effect on locomotor activity in mice or dopamine turnover in rats. In contrast, nicotine produced a biphasic effect on locomotor activity. It also enhanced dopamine turnover rates in the striatum and cerebral cortex, suggesting the involvement of dopaminergic systems in the nicotine-induced changes in locomotor activity. GTS-21 exhibits fewer adverse effects, suggesting that it has therapeutic potential for cognitive disorders related to central cholinergic dysfunction.

Journal

Citations (1)*help

See more

References(24)*help

See more

Details 詳細情報について

Report a problem

Back to top